Skip to content
Review

Real-world evidence supporting sustainable CAR-T-cell therapy-from access to long-term follow-up.

Nov 2026 · International journal of hematology · 0 citations · 70 references
Medicine

TL;DR

This review summarizes major RWE for CAR-T therapies and discusses how RWE can support operational optimization from access through long-term follow-up, and frames the integrated evaluation of basic biology, clinical data, and care processes as "Cytotherapy Operational Science," to discuss its relevance to sustainable CAR-T therapy.

View source

Similar papers

Open access Oct 2026

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...

Jia Xu, Lin Liu, Wei Xie et al. · 0 citations
Open access Sep 2026

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

The outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy are described, to characterise the apheresis-to-infusion interval and the reasons for, and correlates of, failure to reach infusion, and to report progression-free survival (PFS) and overall survival (OS) anchored at the date of...

Ayrton I. Bangolo, Sarvarinder K. Gill, Li-Li Zhang et al. · 0 citations
Review Open access Oct 2026

CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives

Over recent years, chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved outcomes for patients with relapsed or refractory hematological malignancies. Nevertheless, a substantial proportion of patients still experience relapse or progression after treatment, driven by factors including antigen escape,...

Lu-Chen Zhou, Cheng-Cheng Tian, Rui-Qiang Du et al. · 0 citations
Review Open access Sep 2026

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma

The determinants of response and relapse, as well as the mechanisms of antigen-positive and antigen-negative escape that next-generation approaches aim to overcome are discussed, all with the goal of extending durable remissions to every patient.

A. Sperling · 0 citations
Review Open access Oct 2026

Advancing CAR-T Cell Therapy: Biomarker Discovery and Toxicity Management in Pediatric and Young-Adult Populations

CAR-T cell therapy has substantially improved treatment options for relapsed or refractory hematologic malignancies, but clinically important toxicities remain, particularly cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and treatment-related cytopenias. This article pr...

J. Odongo · 0 citations
Review Open access Oct 2026

Early-line immunotherapy in multiple myeloma: reshaping the treatment paradigm

Multiple myeloma (MM) has traditionally been considered to be incurable, despite increasingly effective induction, transplantation, and maintenance strategies. Chimeric antigen receptor (CAR) T-cell therapies and T-cell–redirecting bispecific antibodies have produced deep and durable responses in heavily pretreated dis...

Rida Darji, Curtis Marcoux, Mahmoud R. Gaballa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.